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Edited by Richard MaraisAbstract We have identiﬁed a new guanine-nucleotide ex-
change factor, P-Rex2, and cloned it from human skeletal
muscle and brain libraries. It has widespread tissue distribution
but is not expressed in neutrophils. P-Rex2 is a 183 kDa protein
that activates the small GTPase Rac and is regulated by
phosphatidylinositol (3,4,5)-trisphosphate and the bc subunits of
heterotrimeric G proteins in vitro and in vivo. P-Rex2 has
structure, activity and regulatory properties similar to P-Rex1
but has divergent tissue distribution, as P-Rex1 is mainly
expressed in neutrophils. Together, they form an enzyme family
capable of mediating Rac signalling downstream of G protein-
coupled receptors and phosphoinositide 3-kinase.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The small GTPase Rac (isoforms 1, 2 and 3) regulates a wide
range of cell functions, ranging from cytoskeleton-linked as-
pects such as cell shape, movement, secretion and phagocytosis
to others such as transcription, translation or the production
of reactive oxygen species [1,2]. Deletion of the ubiquitous Rac
isoform Rac1 in mice is embryonic lethal [3], and loss of Rac
function in neutrophils results in immune deﬁciencies in both
human patients and in mouse models [4–7].
Rac, like all Rho-family GTPases, is regulated by guanine-
nucleotide exchange factors (GEFs) [8]. These promote the
dissociation of GDP from Rac, allowing free GTP to bind,
thus rendering the GTPase active. More than a dozen Rac-
GEFs have been identiﬁed so far, including for example the
Vav, Sos and Tiam families. Some of these GEFs are speciﬁc
for Rac, others more promiscuous [8]. Their GEF activities are* Corresponding author. Fax: +44-1223-496-043.
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Abbreviations: P-Rex2, phosphatidylinositol (3,4,5)-trisphosphate-de-
pendent Rac exchanger 2; GEF, guanine-nucleotide exchange factor;
PtdIns(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; PI3K,
phosphoinositide 3-kinase
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phatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3), a lipid
second messenger produced by class I phosphoinositide 3-
kinase (PI3K) [9]. Phosphorylation stimulates, for example,
the Rac-GEF activities of Vav1, Ras-GRF1 and Tiam1
[10–13], while PtdIns(3,4,5)P3 strongly stimulates the Rac-
GEF activities of P-Rex1 and SWAP-70 [14,15] and weakly
those of Vav1, Sos1 and possibly Tiam1 [16–19]. The regula-
tion of P-Rex1 is an exception: it is not only substantially
activated by binding to PtdIns(3,4,5)P3 but also by the bc
subunits of heterotrimeric G proteins, and these two mecha-
nisms can either work independently of each other or in
synergy [14]. P-Rex1 is mainly expressed in neutrophils and is
necessary for full-scale reactive oxygen species formation in
neutrophil-like HL60 and NB4 cells in response to stimulation
of heterotrimeric G protein-coupled receptors [14].
Here, we report the identiﬁcation and characterisation of
Phosphatidylinositol (3,4,5)-trisphosphate-dependent Rac
exchanger 2 (P-Rex2), a homologue of P-Rex1 that is also
activated by PtdIns(3,4,5)P3 and by Gbc subunits and that is
expressed in a wide range of tissues but not in neutrophils.
P-Rex2 is likely to be an important mediator of Rac signalling
that is able to act directly downstream of both G protein-
coupled receptors and class I PI3K.2. Materials and methods
2.1. Materials
Recombinant EE-Rac1, EE-Gb1c2 subunits and EE-tagged P-Rex1
were produced in Sf9 cells, puriﬁed, and stored as previously described
[14]. Recombinant NH2-terminal P-Rex2 was expressed in Sf9 cells,
puriﬁed utilising the EE-tag and stored in PBS, 1 mM EGTA, 1 mM
DTT, 0.01% Na azide, 50% glycerol and 2 mg/ml BSA. D/D-stearoyl-
arachidonyl-PtdIns(3,4,5)P3, the naturally occurring form of
PtdIns(3,4,5)P3, was synthesised by P. Gaﬀney [20].2.2. Cloning of P-Rex2
The existence of P-Rex2 was predicted from searches of the EMBL
database using the TBLASTN programme with the P-Rex1 peptide
sequence [21]. Human skeletal muscle and brain marathon cDNA li-
braries from Clontech were used to clone P-Rex2 by PCR. For this, a
battery of primers was designed on the basis of the sequence prediction
from the EMBL database searches. A full-length clone was assembled
in the pPCRScript vector from Stratagene and sequenced. Subcloning
was done into pCMV3 [22] for expression in mammalian cells with
either NH2-terminal EE- or myc-epitope tags and into pAcoG1 forblished by Elsevier B.V. All rights reserved.
Fig. 1. Domain structure and tissue distribution of human P-Rex2. (A)
Domain structure of human P-Rex2, P-Rex2B and P-Rex1 as pre-
dicted by SMART. The similarity to Inositol Polyphosphate 4-Phos-
phatase was added manually. P-Rex2B is predicted to exist by EMBL
database entry AY508997. (B) Northern blots of P-Rex2 using Clon-
tech Human Multiple Tissue Northern membranes with a cDNA
probe made from nucleotides 2254–3403 of human P-Rex2.
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ment of P-Rex2 and P-Rex1 was done using the CLUSTALX pro-
gramme [23], and protein domain predictions were made using the
SMART programme [24].
2.3. Northern blots
Northern blots were done with Human Multiple Tissue Northern
blotting membranes from Clontech according to the manufacturer’s
instructions using a cDNA probe corresponding to nucleotides 2254–
3403 of human P-Rex2.
2.4. In vitro Rac-GEF assay
Sf9 cell-derived puriﬁed human recombinant P-Rex2 was assayed for
Rac-GEF activity in vitro essentially as previously described [14].
Brieﬂy, GDP-loaded recombinant Sf9 cell-derived puriﬁed EE-tagged
100 nM Rac1 was incubated with 5 nM P-Rex2, [35S]GTPcS and
liposomes (consisted of PC, PS and PI) that either did or did not
contain synthetic PtdIns(3,4,5)P3 or recombinant Sf9 cell-derived pu-
riﬁed Gb1c2 subunits. Rac was then immunoprecipitated using its EE-
tag and its [35S]GTPcS-loading was measured.
2.5. In vivo Rac-GEF assays
Sf9 cells were infected to express P-Rex2, p110c/p101 PI3K and/or
Gb1c2 subunits, serum-starved, and then endogenous GTP-Rac and
GTP-Cdc42 were pulled down from cell lysates using the PAK-CRIB
domain (that binds GTP-loaded but not GDP-loaded Rac and Cdc42
[25]) and visualised by anti-Rac or anti-Cdc42 Western blotting es-
sentially as previously reported [14].
2.6. Immunoﬂuorescence microscopy
Myc-tagged P-Rex2, P-Rex1 or DAPP1 were transiently expressed in
pig aortic endothelial (PAE) cells by electroporation and plated onto
glass coverslips. At 8 h after electroporation, cells were starved for 10 h
in serum-free F12 medium containing 1% fatty-acid-free BSA. Medium
was then replaced with fresh pre-warmed HEPES-buﬀered (pH 7.4,
RT) serum-free F12 medium containing 1% fatty-acid-free BSA. After
60 min, cells were treated with or without 100 nM wortmannin for 10
min and then stimulated for 5 min with or without 10 ng/ml PDGF,
ﬁxed, permeabilised, and double-stained with anti-myc antibody fol-
lowed by Alexaﬂuor 488 anti-mouse antibody (Molecular Probes) and
with TRITC-phalloidin (Sigma) essentially as previously described
[22].3. Results
3.1. Identiﬁcation of P-Rex2
The existence of a homologue of P-Rex1 was predicted from
database searches with P-Rex1 peptide. We named this
homologue P-Rex2, for phosphatidylinositol (3,4,5)-trisphos-
phate–dependent Rac exchanger 2. The gene for human P-
Rex2 lies on chromosome 8, q13.2. Like the gene for P-Rex1,
the P-Rex2 gene is conserved throughout the vertebrates
(Supplementary material Fig. A). No further homologues of
the P-Rex family are predicted to exist.
For the cloning of human P-Rex2, we designed PCR primers
on the basis of the predicted sequence and cloned the full-
length cDNA from human skeletal muscle and brain marathon
cDNA libraries. EMBL database accession code is AJ437636.
The EMBL database also contains two related entries that hint
to the possible existence of alternatively spliced versions of P-
Rex2 (AY508997 and AY508996 and ) (Supplementary ma-
terial Fig. B and Fig. 1A).
Human P-Rex2 is a 183 kDa protein. It has an NH2-ter-
minal DH domain (the typical catalytic domain for GEFs of
Rho-family GTPases) in tandem with a PH domain (phos-
phoinositide-binding domain) followed by two DEP and two
PDZ domains (protein–protein interaction domains) and a
weak homology over its C-terminal half to Inositol Poly-phosphate 4-Phosphatase (Supplementary material Fig. B and
Fig. 1A). P-Rex1 is very similar in size (185 kDa) and has the
same domain structure [14]. Alignments show that P-Rex1 and
P-Rex2 are 59% identical both on the nucleotide and amino
acid levels (Supplementary material Fig. B).
3.2. Tissue distribution of P-Rex2
The tissue distribution of P-Rex2 was investigated by
Northern blotting using Clontech Human Multiple Tissue
Northern membranes with a cDNA probe corresponding to
nucleotides 2254–3403 of human P-Rex2. This showed that P-
Rex2 is widely expressed, most strongly in skeletal muscle,
heart and placenta, but, notably, is absent from peripheral
blood leukocytes (Fig. 1B).
3.3. P-Rex2 is a Rac-GEF in vivo
The similarity between P-Rex2 and P-Rex1 suggested that P-
Rex2 is a Rac-GEF. To test this, we looked at the shape of
PAE cells as a ﬁrst read-out, as this depends on the activation
status of their endogenous Rac (Fig. 2A and B). PAE cells are
kite-shaped when basal and bear membrane ruﬄes and la-
mellipodia when Rac is active, while overexpression of Rac-
GEFs or constitutively active Rac produces spreading and
grossly exaggerated lamellipodia that make the cells look like
fried eggs (denoted here ‘‘active-Rac shape’’) [14,22]. When P-
Rex2 or, for comparison, P-Rex1 were expressed in PAE cells,
some of the transfected cells were ‘‘active-Rac’’ shaped,
whereas control cells were not (Fig. 2A and B), suggesting that
P-Rex2 is a Rac-GEF in vivo.
To expand on this, we next tested whether P-Rex2 can be
activated by PI3K in vivo, by looking for wortmannin-sensi-
tivity of the ‘‘active-Rac’’ cell shape both in unstimulated and
PDGF-stimulated PAE cells (Fig. 2A and B). Wortmannin-
treatment reduced the percentage of P-Rex2-transfected cells
displaying the ‘‘active-Rac’’ cell shape, whereas PDGF-stim-
ulation increased it by 2-fold, and this was also sensitive to
Fig. 2. P-Rex2 is a Rac-GEF in vivo. (A) Confocal immunoﬂuores-
cence micrographs of PAE cells transfected with myc-tagged human P-
Rex2, P-Rex1, or DAPP1, as described in Section 2. Serum-starved
cells were pre-treated with or without 100 nM wortmannin for 10 min,
stimulated with or without 10 ng/ml PDGF for 5 min, as indicated,
and then double-stained with Alexaﬂuor for myc-tagged proteins and
with TRITC-phalloidin for polymerised actin. Confocal micrographs
are from one experiment representative of three. (B) Quantiﬁcation of
results from confocal immunoﬂuorescence micrographs of myc-tagged
human P-Rex2 (2), P-Rex1 (1), or DAPP1 (c) obtained as in (A). One
hundred transfected cells from each coverslip were assessed for their
shape. Spread cells with grossly exaggerated lamellipodia were counted
as ‘‘active-Rac’’. Data are means range from two separate experi-
ments. (C) P-Rex2 Rac-GEF activity in Sf9 cells. Sf9 cells were infected
to express human P-Rex2, p110c/p101 PI3K and/or Gb1c2 subunits as
indicated, serum-starved, and then endogenous GTP-Rac and GTP-
Cdc42 were pulled down using PAK-CRIB and visualised by Western
blotting (top panels; from 4 106 cells/lane) and compared to total-
Rac and total-Cdc42 (bottom panels; lysates from 8 104 cells/lane),
as detailed in Section 2. Data are from one experiment representative
of three.
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mediates the activation of Rac in a PI3K-dependent manner in
vivo.
To test whether P-Rex2 Rac-GEF activity can be stimulated
by Gbc subunits as well as by PI3K in vivo, we used Sf9 cells
which we infected with various combinations of P-Rex2,
p110c/p101 PI3K and/or Gb1c2 subunits. The activity of en-
dogenous Rac was measured using the PAK-CRIB assay
where GTP-loaded Rac is pulled down from cell lysates and
visualised by Western blotting [25]. We used this approach
previously to show that the Rac-GEF activity of P-Rex1 is
synergistically stimulated by PI3K and Gbc subunits [14]. We
found here that, while expression of P-Rex2 with either PI3K
or Gbc subunits alone had only small eﬀects on Rac GTP-
loading (Fig. 2C) (on average 1.5- and 2-fold over basal, re-
spectively, judged by densitometric scanning of Western blots
from three separate experiments), P-Rex2 Rac-GEF activity
was synergistically stimulated by PI3K and Gbc subunits to-
gether (about 7-fold over basal) (Fig. 2C). Hence, P-Rex2 is a
Gbc- and PI3K-dependent Rac-GEF and regulated in a syn-
ergistic fashion in vivo just like P-Rex1.
Next, we used the same Sf9 cell system and PAK-CRIB
assay to look for possible Cdc42-GEF activity of P-Rex2, as
the small GTPase Cdc42 is very similar to Rac. However, P-
Rex2 did not activate Cdc42 under these conditions (Fig. 2C),
which is again the same as previously found for P-Rex1 [14].
3.4. P-Rex2 is activated by PtdIns(3,4,5)P3 and by Gbc
subunits in vitro
To test whether P-Rex2 Rac-GEF activity can be stimulated
by PtdIns(3,4,5)P3 and by Gbc subunits in vitro, we produced
recombinant human P-Rex2 with an NH2-terminal EE-tag in
Sf9 cells and puriﬁed it using its epitope tag (Fig. 3A). For the
in vitro GEF assay, we used this puriﬁed recombinant P-Rex2
with GDP-loaded Sf9 cell-derived puriﬁed recombinant EE-
Rac1 as a substrate in a deﬁned liposome environment and
measured P-Rex2-dependent [35S]GTPcS-loading of Rac.
Using this assay, we measured P-Rex2 Rac-GEF activity
with increasing concentrations of synthetic PtdIns(3,4,5)P3 in
the liposomes. This showed that PtdIns(3,4,5)P3 is suﬃcient
to stimulate P-Rex2 Rac-GEF activity and that its eﬀect is
substantial, with an up to 12-fold activation and an EC50 of
about 0.2 lM (Fig. 3B). We next veriﬁed that the eﬀect of
PtdIns(3,4,5)P3 is through its direct binding to P-Rex2 (rather
than, for example, by changing the liposome environment or
through a charge eﬀect). For this, synthetic PtdIns(3,4,5)P3
was coupled to beads and incubated with Sf9 cell-derived
puriﬁed human P-Rex2 using a method that we have previ-
ously employed to identify many PtdIns(3,4,5)P3-binding
proteins [26]. P-Rex2 bound directly to the PtdIns(3,4,5)P3
beads and could be displaced from the beads only by an
excess of the naturally occurring DD-form of PtdIns(3,4,5)P3
but not by its LL-PtdIns(3,4,5)P3 stereoisomer (data not
shown).
Next, we assayed P-Rex2 Rac-GEF activity with increasing
concentrations of recombinant Sf9 cell-derived Gb1c2 sub-
units. Like PtdIns(3,4,5)P3, the Gbc subunits were suﬃcient to
stimulate the Rac-GEF activity of P-Rex2, and did so sub-
stantially, with a 15-fold activation over basal at 0.5 lM Gbc
subunits (Fig. 3C). These levels of stimulation of P-Rex2 Rac-
GEF activity by PtdIns(3,4,5)P3 and Gbc subunits in vitro are
very similar to those previously found for P-Rex1 [14].4. Discussion
The similarities between the P-Rex2 enzyme we have iden-
tiﬁed here and P-Rex1 [14] are extensive. Both are Rac-GEFs
and regulated by PtdIns(3,4,5)P3 and Gbc subunits. A clue to
Fig. 3. P-Rex2 is directly activated by PtdIns(3,4,5)P3 and by Gbc
subunits. (A) Coomassie-stained SDS–PAGE gel of puriﬁed P-Rex2.
Recombinant human EE-P-Rex2 was produced in and puriﬁed from
Sf9 cells as detailed in Section 2, and its purity assessed by Coomassie-
staining (2 or 4 lg P-Rex2/lane). (B) PtdIns(3,4,5)P3 dose–response of
P-Rex2 Rac-GEF activity. Sf9 cell-derived puriﬁed recombinant P-
Rex2 was subjected to an in vitro Rac-GEF assay as detailed in Section
2 with the indicated concentrations of PtdIns(3,4,5)P3. Data are
means range from two to four separate experiments. (C) Gbc subunit
dose–response of P-Rex2 Rac-GEF activity. As in (B), but with the
indicated concentrations of Sf9 cell-derived puriﬁed recombinant
Gb1c2 subunits instead of PtdIns(3,4,5)P3. Each point has a diﬀerent
cholate concentration (from Gbc subunit storage buﬀer), which has
been corrected for by subtracting an appropriate cholate-only control.
Data are means range from two separate experiments.
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vergent tissue distribution. In neutrophils, where P-Rex1 is
mainly expressed, P-Rex1 regulates the formation of reactive
oxygen species by the NADPH oxidase [14], an enzyme com-
plex that not only requires GTP-Rac as an activating signal
but also as an integral subunit. As the NADPH oxidase is not
expressed in other cell types, P-Rex2 governs presumably the
more general cellular roles of Rac, such as regulation of the
cytoskeleton, transcription and translation. P-Rex2 expression
is highest in skeletal muscle. Interestingly, another Rac-GEF,Trio, is essential for skeletal muscle development, by regulat-
ing the formation of secondary myotubes [27].
Their divergent tissue distribution not only inﬂuences the
cellular roles of P-Rex1 and P-Rex2, but also impacts on the
way they are activated. In neutrophils, one extracellular signal
is suﬃcient to generate both Gbc subunits and PtdIns(3,4,5)P3
and, hence, to fully activate P-Rex1, due to the presence of a
Gbc-regulated form of PI3K, class 1B PI3K [28]. In contrast,
P-Rex2 is expressed in many cell types and tissues that are
thought not to contain class 1B PI3K. Hence, two diﬀerent
extracellular signals are needed to fully activate P-Rex2 in
these tissues, one that stimulates G protein-coupled receptors
to generate Gbc subunits and one that stimulates protein-
tyrosine kinase-linked receptors to generate PtdIns(3,4,5)P3 via
the ubiquitous class 1A PI3K. The contribution of each acti-
vating pathway to the functional importance of P-Rex2 may
even turn out to vary between cell types or receptor types. A
comparable situation can be found for the Rac-GEF Vav1,
regarding the contribution of tyrosine phosphorylation and
PtdIns(3,4,5)P3-binding to its regulation: in B cells, Vav1 Rac-
GEF activity is stimulated by the protein-tyrosine kinase Syk,
and this is not aﬀected by PI3K, whereas in T cells, Fyn-
mediated tyrosine phosphorylation cooperates with PI3K to
activate Vav1 [29].
For P-Rex2, both activating signals, Gbc subunits and
PtdIns(3,4,5)P3, are membrane-bound, and it is generally ac-
cepted that the membrane is the place of action for GEFs.
However, the subcellular localisation of P-Rex2 is mostly cy-
toplasmic, and we did not ﬁnd any large-scale membrane
translocation upon PDGF-stimulation of PAE cells. The sit-
uation is the same for P-Rex1. We assume that low-level
membrane association of the P-Rex enzymes in serum-starved
cells is suﬃcient for Rac activation. However, the importance
of membrane association and translocation is clearly a point of
interest for future work on P-Rex family enzymes.
P-Rex1 and P-Rex2 are unique among GEFs in that they are
directly activated by Gbc subunits. The Rac-GEF activity of
Ras-GRF1 has been reported to be stimulated by Gbc sub-
units, but their eﬀect is indirect by modulating the Rac-GEF’s
tyrosine phosphorylation state [12]. Dbl, a RhoA- and Cdc42-
GEF, can bind Gbc subunits directly via its NH2-terminus,
but this has no eﬀect on its enzymatic activity [30]. Other
classes of enzymes that are directly regulated by Gbc subunits
exist, the class 1B PI3K mentioned above [28] and the PLCb
family [31], but a common Gbc-binding site, equivalent per-
haps to the PH domain as a phosphoinositide-binding site,
does not seem to exist. Future mutational analysis of the P-
Rex family enzymes will be needed to deﬁne where the Gbc
subunits bind and their mechanisms of action.
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